Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Histologic Changes in Superficial Basal Cell Epithelioma and Bowen's Disease by Intralesional Injection of Recombinant Interleukin 2: Recombinant Interleukin 2 May Induce Redifferentiation of Malignant Tumor Cells In Vivo

Histologic Changes in Superficial Basal Cell Epithelioma and Bowen's Disease by Intralesional... Abstract To the Editor.— We describe the antineoplastic effect of recombinant interleukin 2 on malignant tumors of the epidermis by intralesional injection. Report of Cases.— Case 1.—A 44-year-old woman had a 31 × 22 mm, sharply defined plaque on her right waist, whose biopsy specimen was histologically diagnosed as superficial basal cell epithelioma. The lesion was treated by intralesional injection of recombinant interleukin 2 (TGP-3, Takeda Chemical Industries Co, Osaka, Japan). The recombinant interleukin 2 was given at a dose of 1000 U once daily for 13 consecutive days. In the second biopsy performed the day after the last injection, the epidermis had moderate inflammatory cell infiltration, without any necrotic cells or cell debris. Particularly, all basalioma cells were replaced by nearly normal epidermal cells showing orthokeratinization. In the upper aspect of the dermis there were numerous inflammatory cells, including scattered eosinophils. Immunohistochemically, OKT8— positive cells were scattered in considerable numbers References 1. Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects . Immunol Today. 1988;9:58-62.Crossref 2. Dreno B, Hallet MM, Moisan JP, Soulillou JP, Jacques Y. Interleukin 2— like material in human epidermis: a ligand for the human interleukin 2 receptor 55-kD alpha chain . J Invest Dermatol. 1989;93:78-82.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Histologic Changes in Superficial Basal Cell Epithelioma and Bowen's Disease by Intralesional Injection of Recombinant Interleukin 2: Recombinant Interleukin 2 May Induce Redifferentiation of Malignant Tumor Cells In Vivo

Download PDF
1 page

Histologic Changes in Superficial Basal Cell Epithelioma and Bowen's Disease by Intralesional Injection of Recombinant Interleukin 2: Recombinant Interleukin 2 May Induce Redifferentiation of Malignant Tumor Cells In Vivo

Abstract

Abstract To the Editor.— We describe the antineoplastic effect of recombinant interleukin 2 on malignant tumors of the epidermis by intralesional injection. Report of Cases.— Case 1.—A 44-year-old woman had a 31 × 22 mm, sharply defined plaque on her right waist, whose biopsy specimen was histologically diagnosed as superficial basal cell epithelioma. The lesion was treated by intralesional injection of recombinant interleukin 2 (TGP-3, Takeda Chemical Industries Co,...
Loading next page...
 
/lp/american-medical-association/histologic-changes-in-superficial-basal-cell-epithelioma-and-bowen-s-08QVjIAxAN

References (2)

Publisher
American Medical Association
Copyright
Copyright © 1990 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1990.01670320131032
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor.— We describe the antineoplastic effect of recombinant interleukin 2 on malignant tumors of the epidermis by intralesional injection. Report of Cases.— Case 1.—A 44-year-old woman had a 31 × 22 mm, sharply defined plaque on her right waist, whose biopsy specimen was histologically diagnosed as superficial basal cell epithelioma. The lesion was treated by intralesional injection of recombinant interleukin 2 (TGP-3, Takeda Chemical Industries Co, Osaka, Japan). The recombinant interleukin 2 was given at a dose of 1000 U once daily for 13 consecutive days. In the second biopsy performed the day after the last injection, the epidermis had moderate inflammatory cell infiltration, without any necrotic cells or cell debris. Particularly, all basalioma cells were replaced by nearly normal epidermal cells showing orthokeratinization. In the upper aspect of the dermis there were numerous inflammatory cells, including scattered eosinophils. Immunohistochemically, OKT8— positive cells were scattered in considerable numbers References 1. Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects . Immunol Today. 1988;9:58-62.Crossref 2. Dreno B, Hallet MM, Moisan JP, Soulillou JP, Jacques Y. Interleukin 2— like material in human epidermis: a ligand for the human interleukin 2 receptor 55-kD alpha chain . J Invest Dermatol. 1989;93:78-82.Crossref

Journal

Archives of Dermatology – American Medical Association

Published: Aug 1, 1990

There are no references for this article.